Business
Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
PALO ALTO, Calif., May 07, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2026.
About this update from Guardant Health, Inc.
[{"type":"text","content":"First quarter 2026 revenue growth of 48% driven by strong performance in Oncology and Screening","length":95,"tagName":"p","attribs":{}},{"type":"text","content":"Raises 2026 revenue guidance to $1.30 to $1.32 billion, representing growth of 32% to 34%","length":89,"tagName":"p","attribs":{}},{"type":"text","content":"PALO ALTO, Calif., May 07, 2026--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2026.","length":194,"tagName":"p"},{"type":"text","content":"First Quarter 2026 Financial Highlights","length":39,"tagName":"p"},{"type":"text","content":"For the three-month period ended March 31, 2026, as compared to the same period of 2025:","length":88,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Reported total revenue of $301.7 million, an increase of 48%, driven by:","length":72,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47%","length":115,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Biopharma & Data revenue of $53.0 million, an increase of 17%","length":65,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Screening revenue of $41.6 million, and approximately 44,000 Shield screening tests, compared to $5.7 million revenue and 9,000 tests in the prior year period","length":158,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":338,"olType":false}]},{"val":[{"type":"text","content":"Generated non-GAAP gross margin of 66%, compared to 65% for the first quarter of 2025","length":85,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":495,"olType":false},{"type":"text","content":"Recent Operating Highlights","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Presented 38 abstracts at the 2026 American Association for Cancer Research Annual Meeting, highlighting the breadth and strength of the Guardant portfolio","length":155,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Enhanced Guardant360 Tissue capabilities with the addition of whole transcriptome profiling, expanding clinical utility","length":119,"tagName":"p","a...